Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Camrelizumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Camrelizumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Camrelizumab. |
| Estrone | Estrone may increase the thrombogenic activities of Camrelizumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Camrelizumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Camrelizumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Camrelizumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Camrelizumab. |
| Estriol | Estriol may increase the thrombogenic activities of Camrelizumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Camrelizumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Camrelizumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Camrelizumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Camrelizumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Camrelizumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Camrelizumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Camrelizumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Camrelizumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Camrelizumab. |
| Equol | Equol may increase the thrombogenic activities of Camrelizumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Camrelizumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Camrelizumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Camrelizumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Camrelizumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Camrelizumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Camrelizumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Camrelizumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Camrelizumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Camrelizumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Camrelizumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Camrelizumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Camrelizumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Camrelizumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Camrelizumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Camrelizumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Camrelizumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Camrelizumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Camrelizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Camrelizumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Camrelizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Camrelizumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Camrelizumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Camrelizumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Camrelizumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Camrelizumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Camrelizumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Camrelizumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Camrelizumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Camrelizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Camrelizumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Camrelizumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Camrelizumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Camrelizumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Camrelizumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Camrelizumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Camrelizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Camrelizumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Camrelizumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Camrelizumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Camrelizumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Camrelizumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Camrelizumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Camrelizumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Camrelizumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Camrelizumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Camrelizumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Camrelizumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Camrelizumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Camrelizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Camrelizumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Camrelizumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Camrelizumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Camrelizumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Camrelizumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Camrelizumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Camrelizumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Camrelizumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Camrelizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Camrelizumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Camrelizumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Camrelizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Camrelizumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Camrelizumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Camrelizumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Camrelizumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Camrelizumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Camrelizumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Camrelizumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Camrelizumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Camrelizumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Camrelizumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Camrelizumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Camrelizumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Camrelizumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Camrelizumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Camrelizumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Camrelizumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Camrelizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Camrelizumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Camrelizumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Camrelizumab. |